As access to faster and higher-throughput analytical methods becomes increasingly vital, it is critical that we employ superior analytical approaches for mRNA-based therapeutics and vaccines to ensure high quality and effective drugs are approved, whilst adhering to regulatory guidelines.

The industry is reuniting at the 3rd mRNA Analytical Development Summit to seek and discuss new guidelines and identify a path forward with tangible best practices to ensure reliable analytical methods are guiding mRNA production, purification and formulation optimization for approval of high quality, compliant mRNA drugs for patients in need.

Stop by the Areterna Booth to learn how Areterna, a Synthgene company, is fueling the next generation of raw materials and services to enable mRNA and oligo therapeutics.